Arca
Skip to content
Tools
Tools

FN1: Fibronectin

Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin.

  • Drugs that act on it: 7
  • Approved: 1
  • In phases 1 to 3: 6
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on FN1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 1
  • Other 5

Approved1

  • Ocriplasmin

Phase 31

  • L19IL2

Phase 23

  • L19SIP 131I
  • L19TNFA
  • Radretumab

Phase 12

  • AS-1409
  • MU-BC-1

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Philogen S.p.A.343%
  • Antisoma Research114%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 7 act as: Fibronectin binding agent; the rest name their own mechanism.
OcriplasminApprovedThromboGenicsProtein or peptideProteolytic enzymeFibronectin proteolytic enzyme0
L19IL2Phase 3Philogen S.p.A.OtherBinding agent8
L19SIP 131IPhase 2Philogen S.p.A.OtherOtherFibronectin other0
L19TNFAPhase 2Philogen S.p.A.OtherBinding agent0
RadretumabPhase 2—AntibodyBinding agent0
AS-1409Phase 1Antisoma ResearchOtherBinding agent0
MU-BC-1Phase 1—OtherBinding agent0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.

Diseases most associated with it

Open Targets association score, 0 to 1; all associations
  • Spondylometaphyseal dysplasia, 'corner fracture' type0.80
  • Glomerulopathy with fibronectin deposits 20.74
  • Cancer0.63
  • Coronary artery disorder0.59
  • Noonan syndrome0.53
  • Costello syndrome0.50
  • Coronary atherosclerosis0.49
  • Fibronectin glomerulopathy0.48
  • Bacterial infectious disease0.47
  • Abnormality of the skeletal system0.47

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3810, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt P02751, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.